Pharmaceutical

SGNB-7H4V by Pfizer for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

SGNB-7H4V is under clinical development by Pfizer and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma).

Jun 20, 2024 - 04:00
SGNB-7H4V by Pfizer for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
SGNB-7H4V is under clinical development by Pfizer and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma).
Read the original article

Tags:

Previous Article

SGNB-7H4V by Pfizer for Peritoneal Cancer: Likelihood of Approval

Next Article

TYRA-200 by Tyra Biosciences for Bile Duct Cancer (Cholangiocarcinoma): Likeliho...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

EMA and FDA green-light MoonLake to advance IL-17 inhibitor

EMA and FDA green-light MoonLake to advance IL-17 inhib...

Feb 28, 2024

Alfasigma to buy Intercept Pharmaceuticals for $794m

Alfasigma to buy Intercept Pharmaceuticals for $794m

Sep 27, 2023

STAT+: Facing headwinds, Teladoc tests its bet on whole-person care

STAT+: Facing headwinds, Teladoc tests its bet on whole...

Apr 27, 2023